Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Century Therapeutics (IPSC)

Tipranks - Thu Feb 26, 4:52AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jazz Pharmaceuticals (JAZZResearch Report) and Century Therapeutics (IPSCResearch Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

Jazz Pharmaceuticals (JAZZ)

In a report released today, Ami Fadia from Needham maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $235.00. The company’s shares closed last Tuesday at $173.83.

According to TipRanks.com, Fadia is a 5-star analyst with an average return of 25.6% and a 53.4% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Praxis Precision Medicines, and Neumora Therapeutics, Inc. ;'>

Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $228.50, representing a 32.4% upside. In a report released today, TipRanks – OpenAI also upgraded the stock to Buy with a $191.00 price target.

See today’s best-performing stocks on TipRanks >>

Century Therapeutics (IPSC)

Century Therapeutics received a Buy rating from TD Cowen analyst Phil Nadeau today. The company’s shares closed last Tuesday at $2.13.

According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 7.5% and a 48.1% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, XOMA Royalty Corporation, and Apellis Pharmaceuticals. ;'>

Currently, the analyst consensus on Century Therapeutics is a Strong Buy with an average price target of $5.30.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.